Anakinra is recombinant interleukin (IL)-1 receptor antagonist. A new study published in Arthritis & Rheumatism online has found that anakinra is safe and effective for severe Muckle-Wells syndrome.
The researchers investigated the efficacy of anakinra in 12 patients with severe Muckle Wells syndrome. Seven patients were adults and five were children.
All constitutional symptoms resolved by 2 weeks, and there was near complete resolution of musculoskeletal manifestations and significant improvement in ocular symptoms and skin manifestations. [Read more...]